
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is a promising company in the biopharmaceutical industry, with a strong drug candidate in cadisegliatin addressing an unmet need in Type 1 diabetes and potentially expanding its market to Type 2 diabetes. The company's partnerships and other drugs in development show potential for future growth and revenue. However, there are risks and competition that should be considered. With a strong drug profile and potential for revenue growth, vTv Therapeutics has a positive outlook for sustainable success in the treatment of chronic diseases.
Bears say
vTv Therapeutics is heavily focused on developing oral, small-molecule drug candidates, but their current lead candidate, cadisegliatin, has a high risk of failure and limited differentiation from other approved treatments for type 1 diabetes, especially considering the complex and competitive landscape in diabetes treatments. Additionally, vTv's financials show a high reliance on external partnerships and funding to advance their pipeline, adding further risk to their outlook. Overall, the combination of clinical and financial risks make vTv Therapeutics' stock a risky investment.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares